Bioqual Company Description
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.
The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer.
Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays.
In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.
| Country | United States |
| Founded | 1981 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 113 |
| CEO | Mark Lewis |
Contact Details
Address: 9600 Medical Center Drive Rockville, Delaware 20850-3336 United States | |
| Phone | 240 404 7654 |
| Website | bioqual.com |
Stock Details
| Ticker Symbol | BIOQ |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| ISIN Number | US09065J1016 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark G. Lewis Ph.D. | Chairman of the Board, Chief Executive Officer and President |
| Charles C. Kirk Jr., CPA | Chief Financial Officer |
| Mitch Franklin | Chief Operating Officer |
| Hanne Andersen-Elyard Ph.D. | Chief Scientific Officer |